Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Pyridam Farma Tbk's enterprise value is Rp8,325,051 Mil.
PT Pyridam Farma Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was Rp-38,408 Mil. Therefore, PT Pyridam Farma Tbk's EV-to-EBITDA for today is -216.75.
The historical rank and industry rank for PT Pyridam Farma Tbk's EV-to-EBITDA or its related term are showing as below:
ISX:PYFA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -1515.07 Med: 8.02 Max: 94.55
Current: -216.75
During the past 13 years, the highest EV-to-EBITDA of PT Pyridam Farma Tbk was 94.55. The lowest was -1515.07. And the median was 8.02.
ISX:PYFA's EV-to-EBITDA is ranked worse than 100% of 727
companies
in the Drug Manufacturers industry
Industry Median: 13.34
vs ISX:PYFA: -216.75
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Pyridam Farma Tbk's PE Ratio (TTM) for today is calculated as:
PT Pyridam Farma Tbk's share price for today is Rp254.00.
PT Pyridam Farma Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-30.683.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for PT Pyridam Farma Tbk's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PYFA vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Pyridam Farma Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Pyridam Farma Tbk EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Pyridam Farma Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Pyridam Farma Tbk's EV-to-EBITDA falls into.
PT Pyridam Farma Tbk's current Enterprise Value is Rp8,325,051 Mil.
PT Pyridam Farma Tbk's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp-38,408 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Pyridam Farma Tbk (ISX:PYFA) has a EV-to-EBITDA of -216.75 as of Sep. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Pyridam Farma Tbk. According to the industry distribution chart, PT Pyridam Farma Tbk ranks #999999 out of 727 companies in the Drug Manufacturers industry.
Is PT Pyridam Farma Tbk's EV-to-EBITDA too high?
PT Pyridam Farma Tbk's current EV-to-EBITDA is -216.75. Based on the distribution chart, PT Pyridam Farma Tbk ranks #999999 out of 727 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PT Pyridam Farma Tbk has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PT Pyridam Farma Tbk's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Pyridam Farma Tbk ranks #999999 out of 727 companies for EV-to-EBITDA. This places PT Pyridam Farma Tbk in the lower half of its industry. The industry median EV-to-EBITDA is 13.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.34, based on 727 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Pyridam Farma Tbk. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Pyridam Farma Tbk's current EV-to-EBITDA is -216.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Pyridam Farma Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk (ISX:PYFA) is currently considered Modestly Overvalued. The stock's GF Value™ is Rp229.76, compared to a current price of Rp254.00 — trading 10.6% above its estimated fair value. The current EV-to-EBITDA is -216.75. PT Pyridam Farma Tbk's overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Pyridam Farma Tbk (ISX:PYFA), the current EV-to-EBITDA is -216.75 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Pyridam Farma Tbk (ISX:PYFA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Pyridam Farma Tbk stock appears to be overvalued.
The current stock price of Rp254.00 is trading 10.6% above its estimated GF Value™ of Rp229.76.
GuruFocus considers PT Pyridam Farma Tbk to be Modestly Overvalued.
Key valuation signals for ISX:PYFA:
EV-to-EBITDA: -216.75
GF Value™: Rp229.76 vs. price of Rp254.00 (10.6% above fair value)
No single metric tells the full story. See the ISX:PYFA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Pyridam Farma Tbk is engaged in the production and development of pharmaceutical medicines and the trading of medical equipment. It manufactures products namely Antibiotics, Vitamins, Supplements, and Traditional herbal care. It operates through two segments namely Pharmaceutical products, Esthetics, and Toll manufacturing services; and Medical equipment Products segment. The company derives maximum revenue from Pharmaceutical products, Esthetics, and Toll manufacturing services. The company's products include consumer health, Derma, prescription, and biomedilab.
61GF Score
Get the complete analysis for ISX:PYFA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PYFA has been successfully added to your 
